News & Views
Latest News & Views
News & Views
First patient dosed in Phase 1 Trial
Iksuda announces first patient dosed in Phase 1 trial of IKS014
First patient dosed in Phase 1 Trial
Iksuda announces first patient dosed in Phase 1 trial of IKS014
Iksuda enters license agreement with University of Goettingen
Iksuda Therapeutics enters license agreement with University of Goettingen to develop a new generation of antibody drug conjugates
Forging stable relationships for Antibody-Drug Conjugates
DCs are a class of biopharmaceuticals that target cancer cells while leaving healthy cells alone.
Sign up for more news
Thank you